The
rise in Americas obesity rates parallel the rise in consumption of high-fructose
corn syrup, which occurred as manufacturers replaced costlier cane sugar (sucrose)
in drinks and snacks with high-fructose corn syrup (HFCS).
HFCS
is produced by processing corn starch to yield glucose, and then processing the
glucose to create a syrup that is usually about 45 percent fructose and 55 percent
glucose.
Since
sucrose (cane sugar) consists of one molecule of glucose and one molecule of fructose
(i.e., 50 percent each), you'd think its effects would be similar to those of
HFCS. But sucrose behaves very differently in the body, compared with glucose,
fructose, or HFCS.
Conversely,
the bodys digestion, absorption, and metabolism of fructose differ from
the ways it digests, absorbs, and metabolizes glucose or sucrose.
The HFCS-obesity
hypothesis
Americans
consumption of HFCS increased by more than 1,000 percent between 1970 and 1990,
far exceeding the changes in intake of any other food or food group (Bray GA et
al 2004).
HFCS
now represents more than 40 percent of caloric sweeteners added to foods and beverages
and it is the sole caloric sweetener in soft drinks in the United States.
The increased
use of HFCS in the United States mirrors the rapid increase in obesity, and the
way in which the liver metabolizes fructose favors creation of new body fat.
In addition,
unlike glucose, fructose does not stimulate secretion of insulin or leptin: hormones
that act as key signals in the regulation of food intake and body weight (Teff
KL et al 2004).
These
epidemiological and experimental findings explain why many researchers believe
that dietary fructose may promote increased calorie intake and weight gain.
The rise in
HFCS intake also correlates with the rise in rates of metabolic syndrome: a condition
linked to increased risks of type-2 diabetes and cardiovascular disease and characterized
by abdominal obesity, hypertension, and impaired glucose (blood sugar), fat, and
insulin metabolism.
Tellingly,
HFCS produces signs of metabolic syndrome in animal and human studies: especially
elevated triglycerides and altered fat metabolism.
Almost
one in three Americans have symptoms of metabolic syndrome, and according to the
World Health Organization (WHO), some 2.3 billion adults will be overweight by
the year 2015 while more than 700 million people, many of them children, will
suffer from obesity.
There
are some problems with claims that HFCS is a major cause of obesity or metabolic
syndrome:
The
rise in Americas obesity rates also parallels the rise in consumption of
soybeans and soy oil, which are high in omega-6 fatty acids, which promote inflammation
and other obesity-fueling effects.
Obesity
is also rising in countries where cane sugar still dominates.
Most
studies of the effects of fructose have been in rodents, and those in humans have
produced mixed results with regard to insulin resistance: a key pre-diabetic,
obesity-promoting condition.
Still,
the evidence against HFCS seems to be mounting.
As
researchers at Children's Hospital of Pittsburgh wrote recently, High-fructose
consumption is associated with insulin resistance and diabetic dyslipidemia [unhealthful
blood-fat profiles] But, as they also said, the underlying
mechanism is unclear. (Qu S et al 2006)
New
research from Spain may shed some light on the mystery.
Barcelona
study details fructose effects on the liver
The
authors of an animal study in Spain report some disturbing findings about the
way in which fructose is metabolized: outcomes that may bolster the accusations
made against HFCS, and increase calls to remove it from foods and beverages (Roglans
N et al 2007).
Researchers
from the University of Barcelona found that liquid fructose changes the way the
livers in rats metabolize fat. Fructose affects a genetic switch called PPAR-alpha
in ways that impair the liver's ability to break down the sweetener.
As the Spaniards
noted, Because PPAR-alpha activity is lower in human than in rodent livers,
fructose ingestion in humans should cause even worse effects, which would partly
explain the link between increased consumption of fructose and widening epidemics
of obesity and metabolic syndrome. (Roglans N et al 2007)
PPAR-alpha
is believed to help regulate the burning of body fat (fatty acid oxidation).
Researchers
led by Dr. Juan Carlos Laguna fed lab rats a fructose- or glucose-sweetened liquid
(10 percent sugars by volume).
The
livers of the animals drinking the fructose-sweetened liquid metabolized the syrup
differently, yielding a calorie overload to which the animals bodies could
not adapt.
Dr.
Lagunas team report that dietary fructose increased fat synthesis in the
animals' livers and also acted on the PPAR-alpha receptor to reduce breakdown
of the fructose.
As
he said, The most novel finding is that this molecular mechanism is related
to an impairment in the leptin signal. Leptin is a hormone that plays a key role
in the body's energy control; among its peripheral actions, it accelerates fat
oxidation in the liver and reduces its synthesis. (Roglans N et al 2007)
The Spaniards
also observed that fructose decreased fat-burning in the animals' livers (thereby
increasing levels of blood triglycerides and body fat) and activated the pro-inflammatory
(hence, pro-obesity) genetic switch called NF-kappaB: two negative changes not
observed in the glucose-fed rats
No
weight differences seen: short study duration blamed
The
Spanish scientists found no significant differences in weight between the rats
drinking liquids with glucose or fructose, possibly because this study was too
short for such changes to be measurable.
Even
though manufacturers call fructose fruit sugar -- to mislead and lull
consumers of added fructose -- most fruits have much more sucrose than fructose,
and the implications of this study have no bearing on the fructose in fruit.
As Dr. Laguna
said, Fruit is healthy and its consumption is strongly recommended. Our
study focuses on liquid fructose intake as an addition to the ordinary diet.
Editor's
note: We
consider organic whole foods from both plant and animal kingdoms to be a major
key to superior health. We also think it's terribly important to eat fish at least
twice a week to get the essential fatty acids. Here at our house, we only eat
wild Alaskan salmon and other wild seafoods from our friends at Vital Choice.
Click here
to visit Vital Choice Seafood.
Sources:
* Roglans N, Vila
L, Farre M, Alegret M, Sanchez RM, Vazquez-Carrera M, Laguna JC. Impairment of
hepatic Stat-3 activation and reduction of PPARalpha activity in fructose-fed
rats. Hepatology. 2007 Mar;45(3):778-88. * Bray GA, Nielsen SJ, Popkin BM.
Consumption of high-fructose corn syrup in beverages may play a role in the epidemic
of obesity. Am J Clin Nutr. 2004 Apr;79(4):537-43. Review. Erratum in: Am J Clin
Nutr. 2004 Oct;80(4):1090. * Teff KL, Elliott SS, Tschop M, Kieffer TJ, Rader
D, Heiman M, Townsend RR, Keim NL, D'Alessio D, Havel PJ. Dietary fructose reduces
circulating insulin and leptin, attenuates postprandial suppression of ghrelin,
and increases triglycerides in women. J Clin Endocrinol Metab. 2004 Jun;89(6):2963-72.
* Qu S, Su D, Altomonte J, Kamagate A, He J, Perdomo G, Tse T, Jiang Y, Dong HH.
PPAR{alpha} mediates the hypolipidemic action of fibrates by antagonizing FoxO1.
Am J Physiol Endocrinol Metab. 2007 Feb;292(2):E421-34. Epub 2006 Sep 19.
* Le KA, Faeh D, Stettler R, Ith M, Kreis R, Vermathen P, Boesch C, Ravussin E,
Tappy L. A 4-wk high-fructose diet alters lipid metabolism without affecting insulin
sensitivity or ectopic lipids in healthy humans. Am J Clin Nutr. 2006 Dec;84(6):1374-9.
* Wei Y, Wang D, Topczewski F, Pagliassotti MJ. Fructose-mediated stress signaling
in the liver: implications for hepatic insulin resistance. J Nutr Biochem. 2007
Jan;18(1):1-9. Epub 2006 Jul 18. Review. * Le KA, Tappy L. Metabolic effects
of fructose. Curr Opin Clin Nutr Metab Care. 2006 Jul;9(4):469-75. Review.
Disclaimer:
Throughout this website, statements are made pertaining to the properties and/or
functions of food and/or nutritional products. These statements have not been
evaluated by the Food and Drug Administration and these materials and products
are not intended to diagnose, treat, cure or prevent any disease.